Webinar: Optimised workflow for rapid identification of neutralising antibodies against viral particles
Posted: 24 September 2020 | Molecular Devices | No comments yet
Helping in the race to identify effective neutralising antibodies against the spike protein of SARS-CoV-2 virus as the COVID-19 global death rate continues to rise.
The timeline to identify and develop clinically effective neutralising antibodies against viral particles from bench to patient is 18 to 24 months. In this webinar, Molecular Devices scientists demonstrate the steps from clonal selection to cell growth tracking to image-based assurance of monoclonality and show how, using a combination of CloneSelect instruments and screening platforms, the timeline for preclinical development of effective neutralising antibodies can be significantly shortened.
Related content from this organisation
- Episode 11 – CRISPR with Dr Jakob Haaber, SNIPR Biome & Dr Richard Fox, Infinome Biosciences
- How 3D biology is shaping the future of drug discovery
- Molecular Devices launches automated workcells for ELISA workflows
- Episode 8 – 3D imaging with Hilary Sherman, Corning Life Sciences & Dr Oksana Sirenko, Molecular Devices
- Under the microscope: Unveiling a next-generation imaging system with deep learning technology
Related topics
Antibodies, Antimicrobials, Assays, Biomarkers, Biopharmaceuticals, Disease research, Hit-to-Lead, Imaging, Lab Automation, Label-free, Microscopy, Screening, Targets
Related organisations
Molecular Devices
